feedback

Course Director

Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, MBA

Memorial Sloan Kettering Cancer Center
Weill Medical College at Cornell University
New York, New York

Faculty

Robin K. (“Katie”) Kelley
Robin K. (“Katie”) Kelley, MD

Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Professor Riccardo Lencioni
Professor Riccardo Lencioni, MD, FSIR, EBIR

University of Pisa
Pisa, Italy
Miami Cancer Institute
Miami, Florida

Amit Singal
Amit Singal, MD, MS

UT Southwestern Medical Center
Dallas, Texas

Accredited by

Medical Learning Institute, Inc.

Activity Description

Hepatocellular carcinoma (HCC) is an aggressive, complex disease and is a leading cause of cancer-related deaths worldwide. Research endeavors to mitigate HCC mortality have led to rapid advances, especially in the past two years. Today, clinicians specializing in HCC have various treatment options to select for their patients across the spectrum of the disease, and the therapeutic landscape continues to evolve with promising results from ongoing clinical trials investigating novel approaches.

This PeerView MasterClass and Tumor Board on-demand educational activity, based on a symposium held adjunct to the 13th Annual Conference of the International Liver Cancer Association (ILCA 2019), features a panel of multidisciplinary HCC experts who review pivotal evidence on available TKI, antiangiogenic, and checkpoint inhibitor therapies and their optimal treatment sequencing strategies, as well as emerging data on novel combinations and innovative modalities for early- to advanced-stage disease. The experts weave the science into real-world case scenarios, helping to translate the data into practical experiences in the HCC clinic.

Target Audience

This activity has been designed to meet the educational needs of oncologists, hepatologists, gastroenterologists, radiologists, and other clinicians involved in the management of HCC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize recent safety and efficacy evidence of available targeted therapies, such as multikinase inhibitors and monoclonal antibodies, for HCC
  • Evaluate the significance of new data and ongoing clinical trials with checkpoint inhibitors as treatment options for HCC
  • Review the potential use of systemic treatments in novel multimodal strategies for intermediate HCC
  • Construct safe and effective treatment plans across multiple lines of therapy for patients with HCC based on multidisciplinary team–based strategies

Providership, Credit, and Support

This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by medical educational grants from Bayer Healthcare Pharmaceuticals Inc., Celsion Corporation, and Exelixis, Inc.

Physician Continuing Medical Education


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

ACPE Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Ghassan Abou-Alfa, MD, MBA
Attending
Memorial Sloan Kettering Cancer Center
Professor
Weill Medical College at Cornell University
New York, New York

Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 3D Medicines Corporation; Agios, Inc.; Alignmed; Amgen Inc.; AstraZeneca; Bayer; BeiGene; Boston Scientific Corporation; BridgeBio Inc.; Bristol-Myers Squibb; CARsgen Therapeutics; CASI Pharmaceuticals Inc.; Celgene Corporation; Cipla Inc.; Daiichi Sankyo Company, limited; Debiopharm Group; Delcath Systems Inc.; Eisai Inc.; Eli Lilly and Company; Exelixis, Inc.; Flatiron; Genoscience Pharma; Halozyme, Inc.; Hengrui Therapeutics, Inc.; Incyte Corporation; Inovio Pharmaceuticals, Inc.; Ipsen Biopharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Klus Pharma Inc; Kyowa Kirin, Inc.; LAM Inc.; Merck & Co., Inc.; MINAPHARM Pharmaceuticals; Novella; Onxeo; PCI Biotech; QED Therapeutics; Redhill; sanofi-aventis U.S. LLC; Servier; SillaJen, Inc.; Tekmira; twoXAR; VIVUS Inc.; Yakult Pharmaceutical Industry Co., Ltd.; and Yiviva.
Grant/Research Support from ActaBiologica; Agios, Inc.; Array BioPharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; CASI Pharmaceuticals Inc.; Celgene Corporation; Eli Lilly and Company; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Halozyme, Inc.; Incyte Corporation; MabVax Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; OncoQuest Inc.; Polaris Puma; and QED Therapeutics.
Other Financial or Material Support from Spouse consulting for Bioline; Celgene Corporation; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Merck & Co., Inc.; Pfizer Inc.; Silenseed LTD; Sobi, Inc; Targovax; and twoXAR.

Faculty
Robin K. (“Katie”) Kelley, MD
Associate Professor of Clinical Medicine
Helen Diller Family Comprehensive Cancer Center
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Robin K. (“Katie”) Kelley, MD, has a financial interest/relationship or affiliation in the form of:
Other Financial or Material Support from Investigator on Clinical Trials for Adaptimmune; Agios, Inc.; AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; Exelixis, Inc.; MedImmune; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; QED Therapeutics; and Taiho oncology, Inc. lOMC member of Genentech, Inc./ F. Hoffmann-La Roche Ltd.

Professor Riccardo Lencioni, MD, FSIR, EBIR
Department of Radiology, University of Pisa
Pisa, Italy
Hon. Res. Prof. Interventional Oncology
Miami Cancer Institute
Miami, Florida

Professor Riccardo Lencioni, MD, FSIR, EBIR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca and Celsion, Inc.

Amit Singal, MD, MS
Medical Director of Liver Tumor Program
Associate Professor of Medicine
UT Southwestern Medical Center
Dallas, Texas

Amit Singal, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer Corporation; Bristol-Myers Squibb; Eisai Inc.; and Exelixis, Inc.
Other Financial or Material Support from Target MCC for Steering Committee.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Steve S. Choi, MD
Teresa Haile, RPh, MBA

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@peerview.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC credit. There are no pre-requisites and there is no fee to participate in this activity or to receive MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.